Approved · Waiver · decided in 15 days, 1 Apr 2026
Private equity firm Cinven, via Rosewood AG, LP, is acquiring voting rights in Collagen Holdings, LLC (Regenity), a global developer and manufacturer of bioresorbable technologies. This share acquisition will result in Cinven Limited and existing investor Linden Capital Partners having joint control of Regenity.
Rosewood AG, LP, a Guernsey limited partnership (indirectly owned by the Eighth Cinven Fund) proposes to acquire voting rights in Collagen Holdings, LLC (trading as Regenity) (the Acquisition). The Eighth Cinven Fund is indirectly managed and controlled by Cinven Limited. Cinven Limited has exclusive authority to make investment and management decisions for Eighth Cinven Fund. Eighth Cinven Fund and Cinven Limited are part of Cinven. Cinven is a private equity firm engaged in the provision of investment management and investment advisory services to a number of investment funds. The controlled companies in Cinven’s portfolio of investments are active in a variety of sectors including business services, consumer, financial services, healthcare, industrials and technology, media and telecommunications. The Acquisition will result in Cinven Limited and the existing investor, Linden Capital Partners, having joint control of Regenity. Linden Capital Partners is a Chicago-based private equity firm focused exclusively on the healthcare industry. Regenity is a global developer and manufacturer of bioresorbable technologies. The company is headquartered in Paramus, New Jersey.